The funding for 2 million people to receive the twice-yearly preventative treatment lenacapavir is ‘receding in the chaos’ of ...

Lenacapavir works to both treat and prevent HIV, making it a promising drug should it be approved by the FDA later this month.

FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Walmart's Flipkart has secured a lending licence from the Indian central bank and banking regulator, enabling it to offer ...

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...